Drug-induced movement disorders in older adults: An overview for clinical practitioners

Consultant Pharmacist

Volumn 22, Issue 2, 2007, Pages 149-165

  Detweiler, Mark B ^a,b   Kalafat, Naciye ^c   Kim, Kye Y ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c Carilion UVA Roanoke Salem Program   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Akathisia; Dyskinesia; Dystonia; Medications; Movement disorders; Older adults; Parkinsonism

Indexed keywords

AMANTADINE; AMOXAPINE; AMPHETAMINE; ANTIHISTAMINIC AGENT; APOMORPHINE; BENZODIAZEPINE; BROMOCRIPTINE; CAPTOPRIL; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CISAPRIDE; CLOZAPINE; CYTARABINE; DIGOXIN; ETHOSUXIMIDE; FENFLURAMINE; FLUNARIZINE; FLUOXETINE; LEVODOPA; LITHIUM; METHYLDOPA; METHYSERGIDE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PHENELZINE; PHENYTOIN; RESERPINE; UNINDEXED DRUG; VINCRISTINE;

AGED; AKATHISIA; CINAHL; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DYSTONIA; HUMAN; INCIDENCE; INTERNET; LOW DRUG DOSE; MEDLINE; MOTOR DYSFUNCTION; PARKINSONISM; PRIMARY MEDICAL CARE; PSYCINFO; REVIEW; RISK FACTOR; TARDIVE DYSKINESIA;

EID: 34250661095     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.149     Document Type: Review

References (123)

1. Goldberg RJ. Tardive dyskinesia in elderly patients: an update. J Am Med Dir Assoc 2003;4:(suppl):S33-S42.
2. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.
3. Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998;19:57-72.
4. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-84.
5. Diederich NJ, Goetz CG. Drug-induced movement disorders. Neurol Clin North Am 1998;16:125-39.
6. Kaufman DM. Involuntary movement disorders. Clinical neurology for psychiatrists. 5th ed. Philadelphia, PA: W.B. Saunders Company; 2001: 442-509.
7. Grebb JA. Biological therapies. In: Kaplan HI, Saddock BJ, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore, MD: Williams & Wilkins; 1995:1895-909.
8. Jackson GR, Lang AE. Hyperkinetic movement disorders. In: Coffey CE, Cummings JL, eds. Textbook of geriatric neuropsychiatry. Washington, DC: American Psychiatric Press; 2000:530-57.
9. Chen JJ, Swope DM. Movement disorders. In: Chen JE, Miller DA, eds. Drug induced disease, prevention, detection and management. Bethesda, MD: American Society of Health-System Pharmacists; 2005:137-55.
10. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-3.
11. Weiden PJ, Mann JJ, Haas G et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987;144:1148-53.
12. Dixon L, Weiden PJ, Frances AJ et al. Management of neuroleptic-induced movement disorders: effects of physician training. Am J Psychiatry 1989;146:104-6.
13. Sawle G. Movement disorders in clinical practice. Oxford, UK: Isis Medical Media; 1999:165-6.
14. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;19:623-6.
15. Ballerini M, Bellini S, Niccolai C et al. Neuroleptic-induced dystonia; incidence and risk factors. Eur Psychiatry 2002;17:366-8.
16. Coffey CE, Wilkinson WE, Parashos IA et al. Quantitative cerebral anatomy of the aging human brain: a cross-section study using magnetic resonance imaging. Neurology 1992;42:527-36.
17. Friedman JH. Drug induced parkinsonism. In: Lang AF, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisco, NY: Futura; 1992:49.
18. Friedman JH, Weiden PJ. EPS: a guide to prevention, recognition and treatment in the era of atypical antipsychotics. Brooklyn, NY: John Armstrong & Company; 2000.
19. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1998;145:869-71.
20. Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997;54:2461-77.
21. Miller CH, Mohr F, Umbricht D et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59:69-75.
22. Sachdev P. The epidemiology of drug-induced akathisia: part I. Acute akathisia. Schizophr Bull 1995;21:430-49
23. Nelson DE. Akathisia - a brief review. Scott Med J 2001;46:133-4.
24. Rich SR. Drug-induced movement disorders. Available at http://www. brown.edu/Departments/Clinical_Neurosciences/articles/sr55693.html. Accessed August 28, 2006.
25. Sheikh JI. Anxiety disorders. In: Coffey CE, Cummings JL, eds. Textbook of geriatric neuropsychiatry. Washington, DC: American Psychiatric Press; 2000:347-66.
26. Leong GB, Silva JA. Neuroleptic induced akathisia and violence: a review. J Forensic Sci 2003;48:187-9.
27. Hansen L. A critical review of akathisia and its possible relation to suicidal behavior. Hum Psychopharmacol 2001;16:495-505.
28. Duncan EJ, Adler LA, Stephanides M et al. Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol 2000; 23:169-73.
29. Zubenko GS, Lipinske JF, Cohen BM et al. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 1984;11:143-9.
30. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26:265-70.
31. Lima AR, Weiser KV, Bacalchuk J et al. Anticholinergics for neuroleptic induced acute akathisia (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons; 2004.
32. Fischel T, Hermesh H, Aizenberg D et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic induced akathisia: a comparative double blind study. J Clin Psychopharmacol 2001;21:612-5.
33. Kuloglu M, Atmarca M, Ustundag B et al. Serum iron levels in schizophrenic patients with and without akathisia. Eur Neuropsychopharmacol 2003;13:67-71.
34. Kish SJ, Shannak K, Rajput A et al. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992;58:642-8.
35. Dubovsky SL, Buzan R. Psychopharmacology. In: Coffey CE, Cummings JL, eds. Textbook of geriatric neuropsychiatry. Washington, DC: American Psychiatric Press; 2000:779-827.
36. Janno S, Holi M, Tuisku K et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161:160-3.
37. Halliday J, Farrington S, Macdonald S et al. Schizophrenia surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002;181:422-7.
38. Muscettola G, Barbato G, Pampallona S et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19:203-8.
39. Hausner RS. Neuroleptic induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. J Clin Psychiatry 1983;44:13-6.
40. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. American Psychiatric Association; 2004.
41. Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am 1997;20:821-38.
42. Yagi G, Takamiya M, Kanba S et al. Mortality rates of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. Keio J Med 1989;38:70-2.
43. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: association in chronic schizophrenia. Acta Psychiatr Scand 1987;75:74-7.
44. Raja M, Azzoni A. Tardive dystonia. Prevalence, risk factors and clinical features. Ital J Neurol Sci 1996;16:409-18.
45. Diagnostic and statistical manual of mental disorders, DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
46. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 1983;37:267-76.
47. Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiatry 1960;117:152-3.
48. Correl CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25.
49. Dossenbach M, Erol A, el Mahfoud Kessaci M et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J Clin Psychiatry 2004;65:312-21.
50. Kraepelin EP. Dementia praecox and paraphrenia. Barclay RM, trans. Robertson GM, ed. Edinburgh: E and S Livingstone; 1919.
51. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65(suppl 9):S21-S24.
52. Green BH, Dewey ME, Copeland JRM et al. Prospective data on the prevalence of abnormal involuntary movements among elderly people living in the community. Act Psychiatr Scand 1993;87:418-21.
53. Woerner MG, Kane JM, Lieberman JA et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
54. Saltz BL, Woerner MG, Kane JM et al. Prospective study of tardive dyskinesia in the elderly. JAMA 1991;266:2402-6.
55. Kane JM, Jeste DV, Barnes TRE et al. Tardive dyskinesia: a Task Force report of the American Psychiatric Association. Washington, DC: APA Press; 1992.
56. Yassa R, Jeste DV Gender differences in tardive dyskinesia: a critical review of the literature. Schizophren Bull 1992;18:701-14.
57. Woerner MG, Alvir JM, Saltz BL et al. Prospective study of tardive dyskinesia in the elderly: rates risk factors. Am J Psychiatry 1998;155:1521-8.
58. Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatr 1991;25:119-22.
59. MDVU Resource Library. Tardive dyskinesia. Available at www. mdvu.org/library/disease/TD/TD_dd.html. Accessed August 28, 2006.
60. Hyde TM, Egan MF, Brown RJ et al. Diurnal variation in tardive dyskinesia. Psychiatry Res 1995;56:53-7.
61. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophren Bull 1997;23:583-609.
62. Emsley R, Turner HJ, Schronen J et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 1990;157:585-92.
63. Glazer WM, Morgenstern H, Schooler N et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157:585-92.
64. Klawans HL, Barr A. Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 1982;32:558-9.
65. Schwartz M, Hocherman S. Antipsychotic-induced Rabbit syndrome. Epidemiology, management and pathophysiology. CNS Drugs 2004;18:213-20.
66. Dinan TG, Golden T. Orofacial dyskinesia in Down's syndrome. Br J Psychiatry 1990;157:130-2.
67. Waddington JL, Youssef HA. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptics. Br J Psychiatry 1990;156:106-8.
68. Goldman MB, Luchins DJ. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review. Hosp Community Psychiatry 1984;35:1215-9.
69. Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst 1973;34:167-9.
70. Burke RE, Fahn S, Jankovic J et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-46.
71. Raja M. Tardive dystonia. Prevalence, risk factors and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1995;245:145-51.
72. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1:193-208.
73. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 1990;5:309-21.
74. Szymanski S, Lieberman JA, Safferman A et al. Rib fractures as an unusual complication of severe tardive dystonia [letter]. J Clin Psychiatry 1993;54:160.
75. Dressler D, Oeljeschlager RO, Ruther E. Severe tardive dystonias; treatment with continuous intratechal baclofen administration. Move Disord 1997;12:585-7.
76. Rodnitzky RL. Drug induced movement disorders. Clin Neuropharmacol 2002;25:142-52.
77. Kupsch A, Kuehn A, Klaffke S et al. Deep brain stimulation in dystonia. J Neurol 2003;250(suppl 1):147-52.
78. Weetman J, Anderson IM, Gregory RP et al. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry 1997;63:554-6.
79. Atasoy N, Ustundag Y, Konuk N et al. Acute dystonia during pegylated interferon alpha therapy in a case with chronic Hep B infection. Clin Neuropharmacol 2004;27:105-7.
80. Nasrallah HA, Churchill CM, Hamdan-Allan G. Higher frequency of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1988;145:1455-6.
81. Periut P, Galvez-Jimenez N. Dystonia, tardive. 2004. Available at http://www.emedicine.com/med/topic620.htm. Accessed August 28, 2006.
82. Arana GW, Goff DC, Baldessarini RJ et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145:993-6.
83. Spina E, Sturlale V, Valvo S et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. J Clin Psychopharmacol 1993;8:21-4.
84. Goff DC, Arana GW, Greenblatt DJ et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991;11: 106-12.
85. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology (Berl) 1979;61:261-2.
86. Tardive dyskinesia and tardive akathisias. Beers MH, Berkow R, eds. The Merck manual of geriatrics. 3rd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2000:447.
87. Tarsey D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983;6:91-9.
88. Burke RE. Tardive akathisia. In:Yassa R, Nair NPV, Jeste DV, eds. Neuroleptic-induced movement disorders. Cambridge University Press; 1997:409-24.
89. Rajput AH, Offord KP, Beard CM et al. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-82.
90. Ayd Fa. A survey of drug induced extrapyramidal reactions. J Am Med Assoc 1961;175:1054-60.
91. Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994;5:127-32.
92. Kaplan HI, Sadock BJ. Comprehensive textbook of psychiatry/VI. Baltimore, MD: Williams & Wilkins; 1995.
93. Saltz BL, Woerner MG, Robinson DG et al. Side effects of antipsychotic drugs, avoiding and minimizing their impact in elderly patients. Postgrad Med 2000;107:169-78.
94. Vernon GM. Drug induced & tardive movement disorders. Available at http://www.namiscc.org/newsletters/July01/tardive.htm. Accessed August 28, 2006.
95. Weiner WJ, Lang AE. Movement disorders: a comprehensive survey. Mount Kisco, NY: Futura Publishing Company Inc.; 1989.
96. Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43.
97. Cohen S, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole co-prescription in 2 patients. J Clin Psychiatry 2005; 66:135-6.
98. Yasui-Furukori N, Kondo T, Ishida M et al. The characteristics of side-effects of bromperidol in schizophrenic patients. Psychiatry Clin Neurosci 2002;56:103-6.
99. Trosch MR. Neuroleptic-induced movement disorders: deconstructing extrapyramidal symptoms. J Am Geriatr Soc 2004;52(suppl):S266-S271.
100. Mason MN, Johnson CE, Piasecki M. Ziprasidone-induced acute dystonia. Am J Psychiatry 2005;162:625-6.
101. Detweiler MB, Harpold GJ. Bupropion-induced acute dystonia. Ann Pharmacother 2002;36:251-4.
102. Grebb JA. Medication-induced movement disorders. In: Kaplan HI, Saddock BJ, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore, MD: Williams & Wilkins; 1995:1895-909.
103. Arnone D, Hansen L, Kerr JS. Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care. Psychopharmacol 2002;16:395-7.
104. Alberts VA, Catalano G, Poole MA. Tardive dyskinesia as a result of long-term prochlorperazine use. South Med J 1996;89:989-91.
105. Rodgers C. Extrapyramidal side effects of antiemetics presenting as psychiatric illness. Gen Hosp Psychiatry 1992;14:192-5.
106. Skidmore F, Reich SG. Tardive dystonia. Curr Treat Options Neurol 2005;7:231-6.
107. Yung CY. Case vignettes of movement disorders. Brain Res Bull 1983;11:191-4.
108. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003;30(suppl 1):S101-S107.
109. Fraix V, Pollak P, Van Blercom N et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology 2001;57(10, suppl 3):S60-S62.
110. Luginger E, Wenning GK, Bosch S et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disorders 2000;15:873-8.
111. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91.
112. Snow BJ, Macdonald L, Mcaluey D et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: double-blind, placebo-controlled study. Clin Neuropharmacol 2001;23:82-5.
113. Masso JF, Poza JJ, Lopez de Munain A. Drugs inducing or aggravating parkinsonism: a review. Therapie 1996;51:568-77.
114. Lopez-Alemany M, Ferrer-Tuset C, Bernacer-Alpera B. Akathisia and acute dystonia induced by sumatriptan. J Neurol 1997;244:131-3.
115. Lucena R, Monteria L, Melo A. Cisapride related movement disorders. J Pediatr (Rio J) 1998;74:416-8.
116. Dieckmann K, Maurage C, Rolland JC et al. Torticollis as a side effect of cisapride treatment in an infant. J Pediatr Gastroenterol Nutr 1996;22:336.
117. Rosin MA. Chlorzoxazone-induced spasmodic torticollis. JAMA 1981;246:2575.
118. King H, Corry P, Wauchob T et al. Probable dystonic reaction after a single dose of cyclizine in a patient with a history of encephalitis. Anesthesia 2003;58:257-60.
119. Heath HW, Allen JK. Acute dystonia following standard doses of a cold medicine containing phenylpropanolamine. Clin Pediatr 1997;36:57-8.
120. Masmoudi K, Gras-Champel V, Lemaire-Hurtel AS et al. Extra-pyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases. Rev Med Interne 2005;26:453-7.
121. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus). Epidemiology and management. CNS Drugs 2002;16:165-74.
122. Micheli F, Pardal MF, Gatto M et al. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol 1993;16:315-23.
123. Sandyk R, Kay SR. Drug-induced parkinsonism: relationship to age at onset of schizophrenia. Funct Neurol 1991;6:151-7.